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Hypothesis: A new simplified procedure for encapsulation of antibacterial silver nanoparticles 
by Solid-state Ion Exchange (SSIE) procedure over zeolite Y, followed by deposition of 
sulfadiazine (SD) by dry mixing was examined for the preparation of topical antibacterial 
formulations. The ion-exchange and adsorptive properties of the zeolite matrix were utilized 
for the bactericidal Ag deposition and loading of antibiotic sulfadiazine. 
Experiments: Assessment of the encapsulation efficiency of both active components loaded by 
solid and liquid deposition methods was made by X-ray diffraction, TEM, FT-IR 
spectroscopy and thermogravimetric analysis (TGA). SD release kinetics was also 
determined. 
Findings: Sustained delivery of sulfadiazine has been observed from the Ag-modified zeolites 
compared to the parent HY material. It was found that if SD was loaded in solution, part of 
the zeolite silver ions was released and interacted with SD, forming AgSD. By solid-state SD 
deposition, the reaction between the drug and the silver was restricted within the limits of 
inter-atomic interaction, and total but prolonged drug release occurred.  
 
 
1. Introduction 
 
 
Silver nanoparticles are termed as new-generation of antimicrobials [1]. They have been 
recognized as excellent antimicrobial agents because of their effective biocide ability and 
nontoxicity to human cells [2–6]. According to Bonde et al. [7] the activity of standard 
antibiotics was significantly increased in the presence of silver nanoparticles and that can be 
used effectively against antibiotic-resistant pathogens. 
A new aspect in searching for enhanced bactericidal effect for silver has been demonstrated 
in some researches on the synergistic effects of ionic silver with different antibiotics used in 
the treat- ment of burn wound infections [8,9]. Synergistic effects have also been 
demonstrated for chitosan–silver nanocomposites on strain of Staphylococcus aureus [10], for 
b-lactam antibiotics combined with silver nanoparticles and on strain of Escherichia coli [11]. 
However, no one of these silver containing combined systems have used zeolite materials as 
carrier. 
The ion-exchange capability of zeolites might be used to load drug agents as well as to 
release them. The usage of zeolites as scaffolds for drug delivery is, however, relatively 
scarcely investigated. The substitution of silicon by aluminum atoms in the zeolite framework 
requires the presence of charge compensating counter-ions, usually H+ or transition metal 
elements, which impart unique ion-exchange properties [12]. Because of these properties, 
they have been used to control release of supported silver species with bactericidal action and 
also for drug delivery in model systems [13,14]. 
There are several examples of biomedical applications of zeolites reported in the literature 
for wound treatment [15], herbicide release [16], and drug adsorption from polluted waters 
[13,18–22] including sulfonamide antibiotics [17–19]. Also, stable formation of hybrid 
assembly between zeolite (type L) and bacteria (E. coli) was realized and the exchange of 
specific information as well as the movement of the bacterium has become possible. Thus the 
authors developed an innovative potential phototherapeutic tool (De Cola [20–21]) able to 
target, label, and photoinactivate patho- genic and antibiotic-resistant bacteria. 
Besides the traditional methods for drug encapsulation like adsorption from solution and 
incipient wetness impregnation, different approaches for drug loading in solid-state as 
physical mixing (wet paste), ball milling, high pressure homogenization in water, or wet 
media milling and spray-drying of the drug dissolved in its amorphous/nanocrystalline state 
on the support [22–26] could be employed. 
In our previous papers drug formulations containing resveratrol supported on mesoporous 
silicas and zeolite (Y and BEA) carriers prepared by dry physical mixing in a vibrating ball 
mill mixer have been described [27,28]. Also, Ag modifications obtained by direct or post-
synthesis methods for introduction of silver nanoparticles in MCM-41 and SBA-15 materials 
loaded with SD have been studied [27]. In the present publication, a solid-state encapsulation 
approach for introduction of both silver and sulfadiazine (SD) has been applied, utilizing the 
specific ion-exchange and adsorption properties of Y zeolite support. To the best of our 
knowledge no report on drug systems containing Ag and SD loaded together over a zeolite 
carrier have been published yet. Neither the preparation method, viz. solid-state ion exchange 
of Ag and subsequent mechanical deposition of sulfadiazine over Ag-loaded zeolite has been 
reported. 
Solid state ion-exchange as a method for introduction of mono-, di- and polyvalent cations 
has some advantages over the conventional liquid ion exchange. By the solid encapsulation (i) 
handling of large volumes of salt solutions is not required; (ii) the problem of waste salt 
solution can be avoided and (iii) metal cations may be introduced into narrow pore cavities in 
such cases when the large hydration shell of the cations might prohibit the ion-exchange pro- 
cedure in solution. 
In the present work we attempt to apply this more facile, simplified and efficient 
formulation approach for preparation of drug delivery system containing both the antibiotic 
sulfadiazine and silver as a bactericide component. Commercial zeolite Y with high surface 
area and pore volume, as well as high ion-exchange capacity, was chosen as a support for 
drug loading by the consecutive solid-state procedures. The method developed by us, 
considering the ion-exchange ability of zeolites, made possible the formation of silver 
sulfadiazine (AgSD) as well. AgSD also offers many therapeutic advantages in topical use 
over other silver salts [30]. 
Drug amorphization by different nanosizing procedures, in particular the milling one, are 
widely used from the beginning of the nineties, as an efficient method to increase the drug 
solubility in water and dissolution velocity [22–26]. During the solidstate deposition of 
sulfadiazine, amorphization of SD crystals was also supposed to occur. In the present 
contribution a solid dispersion method was developed for the encapsulation of two medical 
con- stituents, such as SD and Ag, and it was compared with the more popular solvent 
deposition approach. The physico-chemical properties and the SD release kinetics in pH = 5.5 
phosphate buffer over the H- and Ag-form Y zeolite carriers were also evaluated. 
 
2. Experimental 
2.1. Materials and methods 
 
2.1.1. Zeolite Y carrier 
Zeolite Y in its ammonium form was supplied by Zeolyst International (UWE Ohlrogge 
(VF), CBV 500) as a powder with the following characteristics: Si/Al molar ratio of 2.6, 
Na2O = 0.2 wt.%, unit cell size = 24.53 Å, surface area (BET) = 750 m2/g and total pore 
volume of 0.34 cm3/g. The decomposition of the NH4-form was performed by stepwise 
heating in dry N2 as follows: heating up to 300°C, hold for 30 min and then heating from 
300°C to 550°C, hold 90 min. The heating rate was 8 °C/min. The as-obtained parent material 
is designated as HY. 
 
2.1.2. Host–guest system preparation. Ag and sulfadiazine loading 
Solid-state encapsulation method has been used for the preparation of the following 
formulations: (i) parent HY zeolite loaded with SD only, designated as SD/HY(SS); (ii) 
parent HY loaded with Ag only by solid-state ion exchange, AgY(SS), and (iii) SD loaded Ag 
exchanged zeolite, SD/AgY(SS). For comparison, solvent deposition method of SD on the 
parent and Ag exchanged zeolite has been also applied. Details on the preparation procedures 
are described below. 
 
2.1.3. Sulfadiazine loading 
The deposition of  the drug in solid-state was made at room temperature by high-energy dry 
milling of sulfadiazine and HY or AgY(SS) in 0.8:1 weight ratio for 3 min in a DDR-GM 
9458 type vibrational ball mill mixer. The resulting preparations were designated as 
SD/HY(SS) or SD/AgY(SS), respectively. 
Sulfadiazine loading in solution was carried out in a mixture of acetone and methanol (1:1) 
at 37°C applying also 0.8 g of SD per 1 g support. After incubation for 24 h, the mixture was 
centrifuged at 15,000 rpm, rinsed with distilled water, separated by a second centrifugation 
and finely dried at room temperature under vacuum. Depending on the type of support, the as 
prepared samples were designated as SD/AgY(Sol), and SD/HY(Sol), respectively. 
 
2.1.4. Silver loading 
The Ag-exchanged Y zeolite was prepared by solid-state ion exchange (SSIE) technique in 
analogy to reductive SSIE procedure, widely studied formerly by our research group [31,32]. 
As a first step the HY powder material was homogeneously mixed with appropriate amount of 
AgNO3, so as 4.14 mmol Ag/g zeolite Y (21.2 wt.% Ag, an amount corresponding to the 
calculated number of exchangeable proton sites available in the zeolite) to be intro duced. The 
mixing was made in the vibrational mixer for 3 min. Subsequently, a thin layer of the AgNO3 
+ HY mixture was loaded into a Pyrex reactor, heated in dry N2 atmosphere from room tem- 
perature to 450°C at 3°C/min for 90 min. Then the temperature was raised to 520°C and held 
for another 90 min. The inert gas was exchanged by air and the sample was treated at the 
same temperature again for 90 min. The resulting powder was designated as AgY(SS) and 
used for drug loading. 
 
2.2. Methods used 
 
X-ray powder diffraction patterns were recorded by a Philips PW 1810/3710 diffractometer 
with Bregg-Brentano parafocusing geometry applying monochromatized CuKα (λ = 0.15418 
nm) radiation (40 kV, 35 mA) and a proportional counter. 
TEM images were taken using a MORGAGNI 268D TEM (100 kV; W filament; point-
resolution = 0.5 nm) apparatus.  
SEM images were prepared by a Zeiss EVO 40XVP type scanning electron microscope.  
TG analysis was performed by a Setaram TG92 instrument. To follow the AgNO3 
degradation from the as-prepared AgNO3 + HY mixture during the solid-state exchange 
method, heating with 3 °C/min rate up to 500°C in Ar flow was applied. The amount of 
loaded sulfadiazine was controlled by heating of the mixture of SD with HY or with AgY(SS) 
in air, at 5°C/min up to 600°C and hold up for 1 h at the same temperature. 
Attenuated Total Reflection Infrared (ATR-FT-IR) spectra were recorded by means of a 
Varian Scimitar 2000 FT-IR spectrometer equipped with a MCT (mercury-cadmium-tellur) 
detector and a single reflection ATR unit (SPECAC ‘‘Golden Gate’’) with diamond ATR 
element. In general, 128 scans and 4 cm-1 resolution was applied. For all spectra ATR 
correction was performed (Varian ResPro 4.0 software). 
 
2.3. Sulfadiazine in vitro release measurements 
 
For in vitro release studies, 20 mg of the drug-loaded particles were incubated in 500 ml 
phosphate buffer with pH = 5.5 at 37 °C under stirring (100 rpm). At appropriate time 
intervals, 5 ml samples were withdrawn from the release medium, and replaced by the same 
amount of fresh buffer. The concentration of the released sulfadiazine in the samples was 
determined by UV–VIS spectrophotometry at a wavelength of 262 nm. The concentration of 
sulfadiazine was calculated according to the standard curve prepared in the concentration 
range of 3–15 µg/ml (r = 0.996). 
 
3. Results and discussion 
 
It is known that the non-crystalline state of the confined drug is one of the key factors for 
the improvement of its dissolution [33]. Thus, we might expect that the solid-state SD 
encapsulation method can lead to some amorphization of the loaded drug, improving its 
solubility and facilitate its deposition/adsorption. In Fig. 1 the SEM pictures of the parent 
zeolite and its SD loaded for mulation are presented. Aggregates from smaller zeolite particles 
seem to be formed as a result of vibrational ball mill mixing of SD with the zeolite (Fig. 1B). 
XRD analysis gives more detailed information about the crystallinity of the zeolite and SD 
structures (Fig. 2). In accordance with the decreased intensity of the strongest SD reflections 
of the grinded compound (Fig. 2A), it can be concluded that milling have led to substantial 
nanosizing of SD. The strongest XRD lines of the drug are clearly visible when it is deposited 
on the H-form of the zeolite both by solid-state or in solution (Fig. 2B). The intensity of SD 
reflections corresponds to the amount of loaded drug (1:0.8 = zeolite:SD ratio). In the case of 
solid state mixing the intensity of zeolite reflections is proportional with the amount of the 
zeolite in the delivery system, but it significantly decreases as a result of SD deposition in 
solution. Such partial crystallinity loss of the parent HY carrier not only takes place when SD 
is loaded by solution method (Fig. 2B), but also during the solidstate ion exchange procedure 
with AgNO3 upon AgY(SS) preparation (Fig. 2C). The additional solid-state loading with SD 
over Ag-modified zeolite resulted in further amorphization of the carrier. Obviously, the 
intense mechanical grinding upon the subsequent solid-state encapsulation of Ag as well as of 
SD over the parent zeolite, results in loss of crystallinity not only for the drug but also for the 
zeolite carrier as the decrease of its X-ray reflections reveals (Fig. 2C). 
 Fig. 1. SEM images of the parent HY (A) and SD/HY(SS) (B) samples 
 
Compared to the zeolite destructive liquid SD deposition over the unmodified HY carrier, 
the zeolite structure does not suffer further crystallinity collapse when SD is loaded by the 
latter method. The almost unchanged reflections of the zeolite support, small amount of SD 
and formation of higher amount of AgSD, can be observed (Fig. 2C). It is possible AgSD to 
be also formed in SD/AgY(SS) (and not in such small amount), but invisible by XRD because 
of its fine distribution in the pores, in contrast to SD/AgY(Sol) in which AgSD is formed on 
the AgY crystallite surface. 
An issue that arises here is whether the whole amount of silver supplemented in the drug 
system by the solid dispersion method is introduced in the zeolite framework as Ag+ cations, 
replacing the zeolite protons, or it remains on he outer zeolite surface, at least partially, as 
metal or oxide silver species. The XRD analysis of the Ag-containing materials (Fig. 2C) does 
not show any presence of such elements. This could mean that either all silver is introduced as 
a counter-ion or XRD invisible metal particles with a size lower than 5 nm have been formed 
as a result of Ag solid-state encapsulation. 
TEM investigations give some indication about the state of the introduced silver. In Fig. 3 
representative TEM images of AgY(SS) and the both SD loaded Ag-modifications are 
presented. According to the picture, metal particles have been formed on AgY(SS) surface 
(Fig. 3A). This means that after the applied SSIE only part of silver is kept in exchangeable 
positions. The remaining Ag+ has most probably been oxidized to Ag2O and/or subsequently 
reduced to Ag0 upon preparation. Transformation of Ag2O to Ag0 in oxidizing atmosphere has 
first been reported by Jacobs et al. [34] for Ag-exchanged A (LTA structure) and L zeolite 
dehydrated under vacuum at different temperatures. The authors found that Ag32+ clusters are  
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Fig. 2. XRD patterns of SD before and after grinding (A), SD/HY(Sol), SD/HY(SS) and 
parent HY zeolite (B), and SD loaded on AgY in solution and in solid-state (C). 
 
stabilized in the sodalite cavities of zeolite A, but on L zeolite they seem to aggregate, 
originating Agm clusters and afterwards Ag0 particles visible by TEM.  
In case of ZSM-5 zeolite, AbuZied et al. [35] have got to the conclusion that Ag2O and Ag+ 
are simultaneously present over AgZSM-5 prepared by SSIE. The FT-IR and elemental 
analysis data show 95% Ag exchange level and low crystallinity Ag2O phase detected by 
XRD analysis. The authors suggested the occurrence of the following reverse reaction: 
 
2ZO-H+ + Ag2O ↔ 2ZO-Ag+ + H2O 
 
generating simultaneously Ag+ and Ag2O nanoparticles in dependence of the temperature and 
the environment. Thus, one can conclude that Ag cations and metal/oxide Ag particles exist 
together over our AgY(SS) formulation prepared by the solid dispersion method. 
 Fig. 3. TEM images of AgY(SS) (A), SD/AgY(SS) (B) and SD/AgY(Sol) (C) samples. 
 
Small Ag nanoparticles with 5–10 nm size as well as largeraggregates (about 50 nm), are 
visible in Fig. 3A. However, the bigger metal particles have not been detected upon our XRD 
measurements. The most possible explanation of this effect is that agglomeration of silver 
nanoparticles upon interaction with the electron beam in the TEM apparatus has taken place 
in accordance with the investigations of Diaz and Mayoral [36]. The authors recommend a 
necessity of careful analysis of the TEM results taken from-beam sensitive materials such as 
silver. 
Loading the Ag-zeolite with sulfadiazine by the solvent or the solid-state method does not 
change significantly the TEM image (Fig. 3B and C). Only overflow from melted SD 
crystallites with droplet shape come into view in these figures. The drug also seems to be 
sensitive and get melted, most probably, under the electron beam. 
FT-IR spectra in the hydroxyl stretching region can prove the occurrence of an exchange 
reaction between the zeolite protons and silver, generating cationic silver upon the SSIE 
procedure.  
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Fig. 4. FT-IR spectra of parent HY and Ag modified AgY(SS) sample, prepared by SSIE. 
 
The observed intensity decrease of the band at 3640 cm-1 and the disappearance of the 3540 
cm-1 band of the AgY(SS) sample, related to the typical low and high frequency ν(OH) 
stretching vibrations of Y zeolite framework [37], is an indication that such SSIE has occurred 
upon the high temperature treatment of AgNO3 and HY mixture. It appears that a substantial 
part of the OH groups of the carrier has been consumed by encapsulation of Ag in cationic 
positions (Fig. 4).  
ATR FT-IR method was also used to ascertain whether some interaction between the 
adsorbed SD molecules and the porous carrier, parent or Ag-modified, occurred. The 
spectrum of the unsupported SD reveals the characteristic stretching vibration bands of amine 
and sulfonamide groups in the 3500–3000 cm-1 range, viz. 3493–3463 cm-1 for the 
asymmetric NH2 stretching vibration (νasym), and the symmetric one between 3390– 3359 cm-1 
(νsym), (Fig. 5A) and also the corresponding bending frequencies (δNH2) at 1629–1627 cm-1 
(Fig. 5B). In respect to νNH vibration of SD, if it is adsorbed on the H+ form of the zeolite, 
the stretching vibration of the formed –NH2+ group will strongly overlap with that of the 
amine νsymNH2, and as Braschi et al. [17] have stated, this will make difficult its precise 
identification. The occurrence of ionic bonding between zeolite Y and different sulfonamides 
including SD is thoroughly studied in the extensive research of these authors. They suppose 
protonation of the sulfa drug by the zeolite protons via van der Waals forces and weak H-
bonding of the loaded SD and the zeolite cage surfaces. Compared to the bare SD, the 
υasymNH2 and υsymNH2 of SD at 3419 and 3352 cm-1, respectively, are slightly shifted in our 
case toward higher wavenumber, i.e. to 3423 and 3355 cm-1 (Fig. 4B). This phenomenon is  
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Fig. 5. FT-IR spectra of SD supported by solid or by solvent deposition method on 
unmodified and Ag-modified zeolite carriers in the 3500–3000 cm-1 region (amine and 
sulfonamide groups) (A), and in the NH2 deformation, aromatic ring vibration and pyrimidine 
moiety (1200–1700 cm-1) region (B). 
 
opposite to the usual frequency down shift due to H-bonding. The νNH stretching assigned to 
3260 cm-1 does not show any changes. In the case of SD/AgY(sol) sample, however, new 
vibration bands at 3389 and 3342 cm-1 come into view. The appearance of these bands is an 
evidence for the formation of AgSD, supported also by the XRD results.  
As to the fingerprint region of the spectrum of SD, it is dominated by the NH2 deformation 
at 1653 cm-1, aromatic ring stretching (νCC at 1576 cm-1) and bending (δCCH at 1487 cm-1), 
and that of pyrimidine moiety (δCCH at 1439 cm-1 and δHCN at 1406/1408 cm-1, Fig. 4C). 
The relative broad band around 1322 cm-1 can be assigned to S–O stretching.  
For both HY and AgY supports, the band shift of aromatic ring and pyrimidine moiety 
vibrations indicates interaction of the benzene (pyrimidine) ring with the zeolite framework. 
For AgY sample loaded with SD by liquid deposition, moreover, bands characteristic for 
AgSD can be witnessed at around 1597, 1581 and 1552 cm-1. The same phenomenon was 
experienced also in the case of SD loaded AgMCM-41 samples [29]. The band at 1552 cm-1 is 
present in the spectra of silver sulfadiazine (AgSD) compound and is assigned to the shifted 
ring vibrations of pyrimidine by the presence of Ag+. The appearance of these bands can be 
due either to the interaction of zeolitic silver cations or metallic silver particles with the 
adsorbed SD resulting in the formation of AgSD. To derive AgSD was actually our intention 
and final goal, viz. to test the ability to get AgSD-loaded formulation overcoming the 
extremely low solubility of this therapeutic compound. 
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Fig. 6. TG (A) and DTG (B) profiles of SD-loaded parent and Ag-modified zeolite Y by solid 
dispersion and solvent deposition method. 
 
Thermogravimetric analysis (TG) has been used to follow the decomposition of AgNO3 
upon the process of silver encapsulation by SSIE (not shown) as well as for quantification of 
the amount of loaded SD. TG analysis of the SD loaded formulations (Fig. 6) showed that 
with the exception of SD/AgY(Sol), the determined amount of the adsorbed drug 
corresponded roughly to the added amount (in 87–100%) prepared either by solid-state or by 
solvent method. However, only about 70% of the loaded SD is found to be adsorbed over 
AgY, when SD was loaded in solution (Fig. 6A). It should be noted here that comparing the 
DTG profiles of the drug decomposition, the low temperature peak of this sample is split (Fig. 
6B) with Tmax values of 236°C and 248°C. This also indicates that another compound that 
could be AgSD has been formed upon the procedure of SD deposition as a result of an ion 
exchange occurred between the Ag ions of the zeolite and the protons of SD. This Ag-
containing product should be eliminated, together with the remaining SD, upon heating. 
Indeed, close decomposition maximum in the same temperature interval, differing by about 
20 °C, (i.e. at 270°C and at 293°C) is observed when the individual, unsupported drugs SD 
and AgSD are heated at the same experimental conditions in the microbalance (not shown). 
The suggestion about occurrence of ion exchange phenomena upon SD loading but only in 
liquid phase over the Ag-modified zeolite is in agreement with the FT-IR data (Fig. 4C) 
showing a band at 1552 cm-1 indicating formation of AgSD. 
Considering the TG decomposition profiles of the SD loaded materials it could be inferred 
that the presence of silver on the sup- port strongly influences the interaction of the drug 
molecule with the zeolite carrier and respectively its way of decomposition. The TG profiles 
of the high temperature SD removal from the H-form of the zeolite are similar regardless of 
the method of its deposition, solvent or solid-state. In the case of Ag-modified carriers, 
however, they are quite different. When solvent deposition method is applied, the dissolved 
SD can react with the Ag+ surface cations or with the Ag+ released to the solvent. In this latter 
case superficial precipitation of AgSD occur on the zeolite particles and its decomposition at 
heating, together with that of SD, would be faster and easier (Fig. 6B). 
Also, the presence of high amount of finely dispersed silver nanoparticles (see TEM results, 
Fig. 3) on the surface of the zeolite crystallites may block the entrances of the zeolite pore 
system and prevent the access of SD into it, thus reducing the adsorption capacity of this 
preparation. It should be noted here that when zeolite materials are used as carriers, the 
molecular sieve effect should not be neglected. When Ag has been incorporated into cationic 
framework positions, a decreased size of the zeolite channels is to be expected as well. The 
latter will cause, in presence of the solvent molecules in particular, diffusion restrictions for 
the drug occlusion. Thus, when the drug is loaded by solvent deposition method, only partial 
SD loading, accompanied by superficial AgSD formation would take place as also the TG 
curve of SD/AgY(Sol) has indicated.  
Upon the first silver deposition step by solidstate ion exchange, a loss of zeolite crystallinity 
has occurred, which has reduced its further adsorption ability during the solvent method of SD 
loading. These effects could also be the reason for the observed lower amount of loaded drug 
(Fig. 6A), for the weaker interaction with the surface, and for the lower decomposition 
temperature of the active substance.  
By applying the solid-state deposition method the above mentioned disadvantages can be 
overcome. The diffusion restrictions caused by the solvent molecules are avoided and 
undisturbed encapsulation of SD inside the zeolite channels might take place upon the intense 
mixing procedure. As a result, precipitation of AgSD on the principle of ‘‘contact-induced ion 
exchange’’ in the zeolite intra-crystalline water [38] can also occur. This could impede the 
removal of the decomposition products out of the zeolite channels as the DTG data indicates, 
considering the appearance of the high temperature degradation peak with Tmax at 518°C (Fig. 
6B). Naturally, upon this method of drug loading, the whole amount of added SD is available 
and the whole amount of degradation products removed upon heating is detected by TG (Fig. 
6A). The concentration of sulfadiazine released in phosphate buffer with pH = 5.5 as a  
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Fig. 7. Sulfadiazine release in pH = 5.5 buffer from the parent and the Ag-modified zeolite Y 
loaded with SD by solid dispersion and by solvent deposition method. 
 
function of time was determined by UV–Vis spectrophotometry at a wavelength of 262 nm. 
The applied release media simulated the physiological conditions for release of dermatological 
formulations. In Fig. 7 the delivery profile of the grinded sulfadiazine substance is compared 
with that of SD loaded (in solid-state or in solution) parent HY zeolite as well as of its Ag-
modification. As the results show, the whole amount of the unsupported grinded sulfadiazine 
is delivered practically immediately. A steep release (over 90% of the loaded drug) for the 
first hour is registered for the drug encapsulated into both preparations of the unmodified 
carrier. Complete SD release from the formulations with the H-form of Y zeolite was reached 
in 2 h.  
The release profile of SD from the silver zeolites is quite different and prolonged (Fig. 7). 
Almost 3 h are necessary for the gradual delivery of the drug from the sample prepared by 
solid-state to be completed. This effect is consistent with the TGA result illustrating that much 
higher temperature is needed for decomposition of the loaded drug by this method. Drug 
occlusion into the pores of the support and stronger drug-framework silver ions interaction 
could be the reason for its extended release. This prolonged release of SD is similar to that of 
found on silver containing nanoporous silica materials [29], but much faster than on polymer 
based systems loaded with AgSD [39].  
By SD solution deposition method over Ag-modified Y zeolite, it can be suggested that part 
of the silver counterions are released in the solvent and react with the drug. Thus, insoluble 
AgSD is precipitated on the outer surface of the support as XRD and FT-IR (Fig. 4) results 
have indicated and incomplete SD release is observed for the as-prepared formulation. This 
could be the reason for the significantly lower quantity of SD delivered from the 
SD/AgY(Sol) sample during the release procedure in the buffer. Only half of the superficially 
loaded SD could be registered in the supernatant and the release takes longer time (Fig. 7). 
Therefore, the presence of silver is a key factor for the sorption ability and kinetics of delivery 
of this particular drug from the Ag-containing zeolite support and these characteristics 
strongly depend on the method of prepa- ration of the respective formulation. 
Further study on the antibacterial properties would reveal the efficiency of the combined 
procedure for preparation of both Ag and SD encapsulated drug delivery systems. The 
kinetics and the amount of released silver as well as assessment of the antibacterial action of 
the above zeolite formulations are objects of our next studies. 
 
4. Conclusion 
 
Successful simplified procedure for preparation of dual Ag-sulfadiazine drug delivery system 
has been developed using zeolite Y as a carrier. To the best of our knowledge this is the first 
attempt to introduce both Ag and SD in a Y zeolite matrix by combination of solid-state ion 
exchange with silver and dry mill mixing with sulfadiazine. 
Silver introduced into the HY carrier by solid-state ion exchange has been encapsulated in 
both states, viz. as Ag+ cations and as Ag0/Ag2O nanoparticles. The method of subsequent SD 
loading does not influence its release kinetics when the H-form of the zeolite is used as carrier 
and no noticeably sustained release can be achieved compared to pure SD. The amount of 
deposited SD, the nature of its interaction with the carrier as well as the release kinetics is 
influenced, however, by the presence of silver. These characteristics depend also on the SD 
loading procedure performed in solid-state or in liquid. When SD is loaded in solution, a part 
of the zeolite silver ions is released and interact with SD, forming AgSD and restricting the 
bioavailability of the formulation. By solid-state SD deposition, the reaction between the drug 
and the silver is limited within the limits of inter-atomic interaction, and total but prolonged 
drug release occurs, compared to the unmodi- fied zeolite. Thus, perspective drug release 
systems for topical use in burn injury can be easily prepared by the latter procedure of solid-
state SD encapsulation into Ag-modified zeolite Y. 
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